Medicare Urged To Create Clear Path For Ending Coverage With Evidence Development Restrictions

As CMS faces a possible decision on what further study it will require for an Alzheimer’s drug if granted a traditional FDA approval, work on updating Medicare’s underlying CED policies continues. Stakeholders press their case ahead of December meeting.